L6-F4-2

L6-F4-2 is an experimental peptide mimotope designed to mimic the L6 tumor-associated antigen (also known as Transmembrane 4 L6 family member 1 or TM4SF1), a protein highly expressed on the surface of various human carcinomas, including lung, breast, colon, and ovarian cancers. Identified through phage display technology, this 12-mer peptide was developed as a cancer vaccine candidate to elicit a humoral immune response. By mimicking the conformational epitope recognized by the L6 monoclonal antibody, L6-F4-2 aims to stimulate the production of endogenous antibodies that cross-react with the L6 antigen on malignant cells, potentially mediating tumor clearance through antibody-dependent cellular cytotoxicity (ADCC). Research on this compound was primarily conducted in the late 1990s by scientists at Bristol Myers Squibb and the Pacific Northwest Research Institute.

Other names

L6 mimotope peptideL-6 mimotope peptideL 6 mimotope peptide